Andrew Obenshain

In this engaging discussion, U.S. Representative Jake Auchincloss advocates for sustainable healthcare policies, while Michael Sherman shares insights on funding innovative therapies amidst high costs. Andrew Obenshain emphasizes Bluebird Bio's mission to pioneer gene therapies for genetic diseases. They tackle the complex interplay between innovation and accessibility, proposing collaborative funding models to improve patient access and addressing ethical considerations surrounding expensive treatments. Together, they envision a future where groundbreaking therapies are within reach for all.